反应性神经刺激治疗难治性癫痫的长期结局:单中心100例经验
该单中心回顾性分析纳入2015年9月至2020年12月连续接受反应性神经刺激(RNS)系统植入的100例难治性癫痫患者,平均随访26.3个月(范围1-5.2年)。约80%患者癫痫发作减少≥50%,19例达到无发作,感染是最常见并发症(7%)。RNS治疗超过3年及既往接受切除或消融手术者结局更好。
要点
- RNS植入后约80%患者癫痫发作减少≥50%,19例达到无发作。
- 感染发生率为7%,其中2例需完全移除RNS装置。
- RNS治疗超过3年者达到≥75%发作减少的比值比为1.8(95%CI 1.07-3.09,p=0.02)。
核心结论
- RNS植入在约80%患者中实现癫痫发作减少≥50%,即使未达到无发作,超过68%病例报告发作持续时间、严重程度或发作后状态显著改善。
- 感染(7%)是最常见并发症,既往接受切除或消融手术及RNS治疗超过3年的患者结局更好。
研究设计与样本
- 回顾性分析前瞻性收集的单中心连续病例数据库,纳入2015年9月至2020年12月接受RNS系统植入的难治性癫痫患者100例,术后随访评估无发作及并发症。
主要发现
- 100例患者中,7例发生感染:2例经静脉抗生素治疗好转,3例需部分移除并挽救系统,2例需完全移除RNS装置。
- 本队列未记录到术后穿刺道出血、卒中、装置移位或故障。
- 平均随访26.3个月(范围1-5.2年)。
- 发作改善分布:8例改善0%-24%,14例改善25%-49%,29例改善50%-74%,30例改善75%-99%,19例达到无发作。
- RNS治疗超过3年的患者达到≥75%发作减少的比值比为1.8(95%CI 1.07-3.09,p=0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite antiepileptic drugs, more than 30% of people with epilepsy continue to have seizures. Patients with such drug-resistant epilepsy (DRE) may undergo invasive treatment such as resection, laser ablation of the epileptogenic focus, or vagus nerve stimulation, but many are not candidates for epilepsy surgery or fail to respond to such interventions. Responsive neurostimulation (RNS) provides a neuromodulatory option. In this study, the authors present a single-center experience with the use of RNS over the last 5 years to provide long-term control of seizures in patients with DRE with at least 1 year of follow-up. METHODS: The authors performed a retrospective analysis of a prospectively collected single-center database of consecutive DRE patients who underwent RNS system implantation from September 2015 to December 2020. Patients were followed-up postoperatively to evaluate seizure freedom and complications. RESULTS: One hundred patients underwent RNS placement. Seven patients developed infections: 2 responded to intravenous antibiotic therapy, 3 required partial removal and salvaging of the system, and 2 required complete removal of the RNS device. No postoperative tract hemorrhages, strokes, device migrations, or malfunctions were documented in this cohort. The average follow-up period was 26.3 months (range 1-5.2 years). In terms of seizure reduction, 8 patients had 0%-24% improvement, 14 had 25%-49% improvement, 29 experienced 50%-74% improvement, 30 had 75%-99% improvement, and 19 achieved seizure freedom. RNS showed significantly better outcomes over time: patients with more than 3 years of RNS therapy had 1.8 higher odds of achieving 75% or more seizure reduction (95% CI 1.07-3.09, p = 0.02). Also, patients who had undergone resective or ablative surgery prior to RNS implantation had 8.25 higher odds of experiencing 50% or more seizure reduction (95% CI 1.05-65.1, p = 0.04). CONCLUSIONS: Responsive neurostimulator implantation achieved 50% or more seizure reduction in approximately 80% of patients. Even in patients who did not achieve seizure freedom, significant improvement in seizure duration, severity, or postictal state was reported in more than 68% of cases. Infection (7%) was the most common complication. Patients with prior resective or ablative procedures and those who had been treated with RNS for more than 3 years achieved better outcomes.
引用
- Roa JA, Marcuse L, Fields M, et al. Long-term outcomes after responsive neurostimulation for treatment of refractory epilepsy: a single-center experience of 100 cases. J Neurosurg. 2023. PMID: 37655833. doi:10.3171/2023.2.JNS222116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。